ArticleDiscover oncology2025
Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundProstate cancer (PCa) is a leading malignancy with a rising global incidence, posing significant challenges in treatment. The immunosuppressive tumor microenvironment (TME) in castration-resistant prostate cancer (CRPC) is a major barrier to effective immunotherapy. Identifying therapeutic targets that modulate the immune response within TME is crucial for advancing PCa treatment. MATERIALS AND
methodsIn this study, we employed Mendelian randomization (MR) to investigate the causal relationships between gene expression of blood proteins and PCa risk. We utilized cis-eQTL data from the eQTLGen Consortium and immune cell phenotype data from the NHGRI-EBI GWAS Catalog. Our analysis included primary and secondary cohorts, totaling over 800,000 individuals. Colocalization analysis was performed to confirm the genetic associations, and mediation MR analysis was used to explore the mediating role of proteins in tumor immunity. Drug prediction and molecular docking were applied to assess the potential of identified targets as druggable candidates.
resultsOur MR analysis identified 557 proteins associated with PCa in the primary cohort, with 85 proteins remaining significant in another independent cohort. Mediation analysis revealed nine proteins that mediated the impact of immune cells on PCa. Colocalization analysis confirmed the causality of five proteins, which were further supported by phenome-wide association studies (PheWAS) and protein-protein interaction (PPI) networks. Molecular docking demonstrated strong binding affinity of potential drugs to these targets.
conclusionsThis study identified five drug targets in prostate cancer that modulate the tumor immune response. These targets may expedite drug development and personalize medicine, potentially enhancing treatment efficacy and reducing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.